TXNRD1 and central nervous system cancer: Subsequently, we found that BS1801 also inhibited TrxR1 activity and elevated LDH levels in a dose-dependent manner in TMZ resistant glioma cells (Fig. S5A–F), suggesting that BS1801 may eliminate these glioma cells to relieve TMZ resistance.